Developing targeted conventional therapies hampered by lack of understanding key events/pathways that lead to response/resistance


  • 1

    Lack of validated biomarkers

  • 2

    Co-ordinated molecular analysis of cell lines and clinical trial material has led to identification of histone assay

  • 3

    Assay has been validated in phase III clinical trial

  • 4

    Ongoing studies validating assay to level IA and IB

  • 5

    Histone assay is a potential tool that could be used by clinicians to determine if a patient could be spared anthracycline treatment. ​


Melanie Spears PhD

at Ontario Institute for Cancer Research

Toronto, Ontario, Canada

Comments (0)